Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 09:31 am Purchase |
2024-09-30 | 13G | Immunic, Inc. IMUX |
Adage Capital Management L.P. | 5,594,406 6.210% |
5,594,406 (New Position) |
Filing History |
| 2024-11-12 09:31 am Unchanged |
2024-09-30 | 13G | Molecular Templates, Inc. MTEM |
Adage Capital Management L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2024-11-12 09:31 am Purchase |
2024-09-30 | 13G | Aligos Therapeutics, Inc. ALGS |
Adage Capital Management L.P. | 218,813 7.120% |
218,813 (New Position) |
Filing History |
| 2024-11-12 09:31 am Purchase |
2024-09-30 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Adage Capital Management L.P. | 1,419,792 3.290% |
1,419,792 (New Position) |
Filing History |
| 2024-11-12 09:31 am Purchase |
2024-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO |
Adage Capital Management L.P. | 2,597,736 7.860% |
2,597,736 (New Position) |
Filing History |
| 2024-11-12 09:30 am Purchase |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
Adage Capital Management L.P. | 3,735,741 8.870% |
3,735,741 (New Position) |
Filing History |
| 2024-11-12 09:30 am Purchase |
2024-09-30 | 13G | Solid Biosciences Inc. SLDB |
Adage Capital Management L.P. | 1,754,159 4.550% |
1,754,159 (New Position) |
Filing History |
| 2024-11-12 09:30 am Purchase |
2024-09-30 | 13G | enGene Holdings Inc. Common Stock ENGN |
Adage Capital Management L.P. | 2,329,768 5.270% |
2,329,768 (New Position) |
Filing History |
| 2024-11-04 4:26 pm Purchase |
2024-10-29 | 13D | GlycoMimetics, Inc. GLYC |
Adage Capital Management L.P. | 5,091,231 7.900% |
5,091,231 (New Position) |
Filing History |
| 2024-10-22 4:15 pm Purchase |
2024-10-22 | 13D | Oruka Therapeutics, Inc. ORKA |
Adage Capital Management L.P. | 175,000 0.500% |
175,000 (New Position) |
Filing History |
| 2024-06-03 4:30 pm Purchase |
2024-05-31 | 13G | Abeona Therapeutics Inc. ABEO |
Adage Capital Management L.P. | 4,210,429 9.990% |
4,210,429 (New Position) |
Filing History |
| 2024-05-01 5:08 pm Unchanged |
2024-04-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
Adage Capital Management L.P. | 5,156,299 9.900% |
0 (Unchanged) |
Filing History |
| 2024-04-30 8:53 pm Purchase |
2024-04-30 | 13G | EyePoint Pharmaceuticals, Inc. EYPT |
Adage Capital Management L.P. | 5,156,299 10.350% |
5,156,299 (New Position) |
Filing History |
| 2024-04-05 4:05 pm Purchase |
2024-04-03 | 13D | ARCA biopharma, Inc. ABIO |
Adage Capital Management L.P. | 100,000 8.280% |
100,000 (New Position) |
Filing History |